One target for amyotrophic lateral sclerosis therapy? by Mizielinska, S & Isaacs, AM
Header: Citation (Arial 11 pt italic) 
 
 
 
 
 
 
 
 
 
ARTICLE 
 
One target for amyotrophic lateral sclerosis therapy? 
 
Sarah Mizielinska, Adrian M. Isaacs 
Institute of Neurology, University College London 
 
 
Abstract 
Repeat expansion mutations cause a range of developmental, neurodegenerative, and 
neuromuscular disorders. The repeat sequences generally comprise a 3– to 6–base pair 
repeat unit that expands above a critical threshold, leading to disease. Expanded repeats 
cause disease via a range of mechanisms, including loss of function of the repeat-containing 
protein and production of toxic repeat RNAs and proteins, making the disorders difficult to 
treat. In 2011, a hexanucleotide repeat expansion in the C9orf72 gene was identified as the 
most common cause of frontotemporal dementia and amyotrophic lateral sclerosis (termed 
c9FTD/ALS) (1, 2). On page 708 of this issue, Kramer et al. (3) report that targeting a single 
factor, Spt4, reduced production of C9orf72 repeat expansion–associated RNA and protein, 
and ameliorated neurodegeneration in model systems. 
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